Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Mallinckrodt
Deloitte
UBS
US Department of Justice
Argus Health
Chubb
McKesson
Fuji
Chinese Patent Office

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021367

« Back to Dashboard

NDA 021367 describes FEMRING, which is a drug marketed by Apil and is included in one NDA. It is available from two suppliers. Additional details are available on the FEMRING profile page.

The generic ingredient in FEMRING is estradiol acetate. There are seventy-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the estradiol acetate profile page.
Summary for 021367
Tradename:FEMRING
Applicant:Apil
Ingredient:estradiol acetate
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)
Formulation / Manufacturing:see details
Pharmacology for NDA: 021367
Ingredient-typeEstradiol Congeners
Mechanism of ActionEstrogen Receptor Agonists
Suppliers and Packaging for NDA: 021367
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367 NDA Allergan, Inc. 0023-5868 0023-5868-05 1 POUCH in 1 CARTON (0023-5868-05) > 90 d in 1 POUCH
FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367 NDA Allergan, Inc. 0023-5869 0023-5869-10 1 POUCH in 1 CARTON (0023-5869-10) > 90 d in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INSERT, EXTENDED RELEASE;VAGINALStrengthEQ 0.05MG BASE/24HR
Approval Date:Mar 20, 2003TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INSERT, EXTENDED RELEASE;VAGINALStrengthEQ 0.1MG BASE/24HR
Approval Date:Mar 20, 2003TE:RLD:Yes

Expired US Patents for NDA 021367

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-001 Mar 20, 2003 ➤ Subscribe ➤ Subscribe
Apil FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-002 Mar 20, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Moodys
Chubb
Novartis
Cantor Fitzgerald
Medtronic
Healthtrust
Merck
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot